Asset Purchase Deals in Pharmaceuticals and Biotechnology 2019 to 2026
Asset Purchase Deals in Pharmaceuticals and Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2019 to 2026
Benchmark Asset Acquisition Strategies Across the Global Biopharma Industry
The Asset Purchase Deals in Pharmaceuticals and Biotechnology 2019–2026 report provides a comprehensive analysis of asset acquisition transactions across the global life sciences industry. Designed for business development, licensing, and corporate strategy professionals, the report delivers detailed insight into how companies structure asset purchase deals and negotiate the financial terms behind these transactions.
Fully revised and updated, the report analyzes asset purchase agreements announced since 2019, providing a detailed view of how pharmaceutical and biotechnology companies acquire business assets, product assets, royalty interests, and technology assets through strategic transactions.
Each deal record includes financial terms where available and links to detailed online deal records and contract documents filed with regulators when publicly disclosed. This combination of deal data, financial benchmarking, and contract access enables users to evaluate comparable transactions and structure more effective asset acquisition strategies.
Key Benefits
✔ Save Significant Research Time
Access a consolidated database of asset purchase deals rather than searching multiple press releases, databases, and regulatory filings.
✔ Benchmark Asset Purchase Deal Structures
Understand how pharmaceutical and biotechnology companies structure asset acquisition agreements across business units, products, technologies, and royalty streams.
✔ Analyze Financial Terms with Confidence
Review disclosed financial information—including headline deal values, upfront payments, milestones, and royalty arrangements—to benchmark transaction values and structures.
✔ Access Real Contract Documents
Where available, explore SEC-filed asset purchase agreements, providing deeper insight into the contractual provisions behind real-world deals.
✔ Identify the Most Active Asset Acquisition Dealmakers
Discover which companies are most active in asset acquisitions and analyze their strategic transaction activity.
✔ Track Industry Trends
Analyze asset purchase dealmaking trends since 2019 across companies, therapeutic areas, and technology types.
What’s Included in the Report
-
Analysis of asset purchase dealmaking trends since 2019
-
Overview of asset acquisition deal structures and transaction models
-
Review of the leading asset purchase deals by headline value
-
Profiles of the top 25 most active asset purchase dealmakers
-
Detailed analysis of deals organized by company, therapeutic area, technology type, and industry sector
-
A comprehensive deal directory covering asset purchase transactions announced since 2019
-
Links to online deal records and contract documents where available
Due Diligence Insights from Real Agreements
By reviewing actual asset purchase contracts, the report enables users to evaluate key transaction provisions such as:
-
Asset ownership and transfer rights
-
Financial payment structures and transaction values
-
Intellectual property rights and technology transfer provisions
-
Commercialization and development obligations
-
Royalty structures and ongoing financial participation
-
Contract duration and termination provisions
Access to real agreements provides insight into the detailed terms negotiated between companies—information rarely disclosed in press releases or traditional deal databases.
Why This Report Matters
Asset purchase transactions are an important strategic tool in the pharmaceutical and biotechnology industries, enabling companies to acquire technologies, products, and royalty streams to strengthen their pipelines and portfolios.
By combining comprehensive deal data, financial benchmarking, and access to real contract documents, this report provides the intelligence needed to evaluate acquisition opportunities, structure stronger asset purchase agreements, and negotiate more effectively.
Key Benefits
✔ Save Significant Research Time
Access a consolidated database of asset purchase deals rather than searching multiple press releases, databases, and regulatory filings.
✔ Benchmark Asset Purchase Deal Structures
Understand how pharmaceutical and biotechnology companies structure asset acquisition agreements across business units, products, technologies, and royalty streams.
✔ Analyze Financial Terms with Confidence
Review disclosed financial information—including headline deal values, upfront payments, milestones, and royalty arrangements—to benchmark transaction values and structures.
✔ Access Real Contract Documents
Where available, explore SEC-filed asset purchase agreements, providing deeper insight into the contractual provisions behind real-world deals.
✔ Identify the Most Active Asset Acquisition Dealmakers
Discover which companies are most active in asset acquisitions and analyze their strategic transaction activity.
✔ Track Industry Trends
Analyze asset purchase dealmaking trends since 2019 across companies, therapeutic areas, and technology types.
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in asset purchase dealmaking
2.1. Introduction
2.2. Types of assets purchased
2.3. Trends in asset purchase deals since 2019
2.3.1. Asset purchase dealmaking by year
2.3.2. Asset purchase dealmaking by phase of development
2.3.3. Asset purchase dealmaking by industry sector
2.3.4. Asset purchase dealmaking by therapy area
2.3.5. Asset purchase dealmaking by technology type
2.3.6. Asset purchase dealmaking by most active company
2.4. Reasons for entering into asset purchase partnering deals
2.4.1. Business assets
2.4.2. Product assets
2.4.3. Royalty assets
2.4.4. Technology assets
2.5. The future of asset purchase deals
Chapter 3 – Overview of asset purchase deal structure
3.1. Introduction
3.2. Asset purchase agreement structure
Chapter 4 – Leading asset purchase deals
4.1. Introduction
4.2. Top asset purchase deals by value
Chapter 5 – Top 25 most active asset purchase dealmakers
5.1. Introduction
5.2. Top 25 most active asset purchase dealmakers
Chapter 6 – Asset purchase deals including contracts directory
6.1. Introduction
6.2. Asset purchase deals with contracts
Deal directory
Deal directory – Asset purchase dealmaking by companies A-Z
Deal directory – Asset purchase dealmaking by therapy area
Deal directory – Asset purchase dealmaking by technology type
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering
TABLE OF FIGURES
Figure 1: Definition of assets purchased
Figure 2: Trends in asset purchase deal announcements
Figure 3: Asset purchase deals signed at each phase of development
Figure 4: Asset purchase deals by industry sector
Figure 5: Asset purchase deals by therapy area
Figure 6: Asset purchase deals by technology type
Figure 7: Top 25 most active asset purchase dealmakers
Figure 8: Top asset purchase deals by value
Figure 9: Most active asset purchase dealmakers
Pricing options
- $3,995: single-user (encrypted file - one user/device)
- $5,995: multi-user (encrypted file - up to 5 users/devices)
- $7,995: company (unencrypted file)
Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin PDF Reader will be provided at report delivery.
Company license files are not encrypted and can be accessed using a PDF Reader.
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Biopharma Research Ltd based in County Durham, United Kingdom. We have been trading successfully online since 2012 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
About Current Partnering
A definitive, evidence-based approach to dealmaking intelligence
Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.
Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.
All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.
Our methodology
Built on a continuously updated proprietary database
All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.
Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.
Comprehensive and verifiable data sourcing
Deal data is sourced from publicly available industry disclosures, including:
- Company press releases and announcements
- SEC filings and equivalent regulatory disclosures
- Company and investor presentations
- Conference materials and company websites
All sources are captured and referenced, enabling full transparency and user verification.
Broad coverage across deal types and structures
Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:
- Licensing and co-development
- Research and collaborative R&D
- Manufacturing, supply, and distribution
- Commercialisation and co-promotion
- Equity investments, joint ventures, and asset transactions
- Options, royalties, and financing agreements
This breadth ensures a complete view of how partnerships are structured across the life sciences sector.
Structured, standardised analysis
Every deal is analysed using a consistent framework, capturing (where disclosed):
- Financial terms — including upfront payments, milestones, and royalties
- Rights allocation — development, manufacturing, and commercialization responsibilities
- Deal structure — exclusivity, territorial scope, and agreement type
- Contractual provisions — clauses defining risk, control, and value-sharing
Each deal record is fully categorised, including data fields such as:
- Therapy area and technology type
- Stage of development
- Asset type and deal components
- Geographic scope and exclusivity
- Source documentation, including press releases and SEC filings
Financial normalisation for comparability
All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.
Contract-level insight
Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.
This enables users to understand:
- How financial mechanisms are defined and triggered
- How responsibilities are operationalised between parties
- How flexibility, risk, and control are allocated within agreements
Designed for real-world application
Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including:
- Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy
- Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour
- Advisory, legal, and consulting firms — supporting client engagements with real-world precedent and contract-level insight
Common use cases include:
- Benchmarking comparable transactions
- Supporting valuation and deal structuring
- Preparing for negotiations
- Evaluating potential partners
- Informing internal strategy with real-world evidence
A trusted industry reference
With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies, emerging biotechs, investors, and advisory firms as a trusted source of dealmaking intelligence.
By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.
